# Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

> **NCT02471144** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 162 (actual)

## Conditions studied

- Chronic Severe Plaque-type Psoriasis

## Interventions

- **BIOLOGICAL:** Experimental : Secukinumab low dose
- **BIOLOGICAL:** Experimental: Secukinumab high dose
- **BIOLOGICAL:** Placebo Comparator: Secukinumab Placebo
- **BIOLOGICAL:** Active Comparator: Etanercept

## Key facts

- **NCT ID:** NCT02471144
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-29
- **Primary completion:** 2018-12-13
- **Final completion:** 2023-03-30
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2023-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02471144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02471144, "Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02471144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*